| Product Code: ETC9555860 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Sweden continued to heavily rely on imports of gemcitabine hydrochloride, with Metropolitan France, China, Japan, Finland, and Germany being the top exporting countries. The market remained highly concentrated, as indicated by the high Herfindahl-Hirschman Index (HHI). However, there was a decline in the compound annual growth rate (CAGR) from 2020 to 2024 at -1.48%, with a significant drop in the growth rate from 2023 to 2024 at -9.13%. This suggests a challenging market environment for gemcitabine hydrochloride imports into Sweden, with potential implications for market dynamics and competition among suppliers.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Sweden Gemcitabine Hydrochloride Market Overview |
3.1 Sweden Country Macro Economic Indicators |
3.2 Sweden Gemcitabine Hydrochloride Market Revenues & Volume, 2021 & 2031F |
3.3 Sweden Gemcitabine Hydrochloride Market - Industry Life Cycle |
3.4 Sweden Gemcitabine Hydrochloride Market - Porter's Five Forces |
3.5 Sweden Gemcitabine Hydrochloride Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.6 Sweden Gemcitabine Hydrochloride Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 Sweden Gemcitabine Hydrochloride Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence of cancer in Sweden |
4.2.2 Growing awareness and adoption of chemotherapy treatments |
4.2.3 Government initiatives to improve healthcare infrastructure |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval |
4.3.2 High cost associated with gemcitabine hydrochloride treatment |
4.3.3 Competition from alternative treatment options |
5 Sweden Gemcitabine Hydrochloride Market Trends |
6 Sweden Gemcitabine Hydrochloride Market, By Types |
6.1 Sweden Gemcitabine Hydrochloride Market, By Product Type |
6.1.1 Overview and Analysis |
6.1.2 Sweden Gemcitabine Hydrochloride Market Revenues & Volume, By Product Type, 2021- 2031F |
6.1.3 Sweden Gemcitabine Hydrochloride Market Revenues & Volume, By Injection, 2021- 2031F |
6.1.4 Sweden Gemcitabine Hydrochloride Market Revenues & Volume, By Solution, 2021- 2031F |
6.2 Sweden Gemcitabine Hydrochloride Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Sweden Gemcitabine Hydrochloride Market Revenues & Volume, By Breast Cancer, 2021- 2031F |
6.2.3 Sweden Gemcitabine Hydrochloride Market Revenues & Volume, By Non-small Cell Lung Cancer, 2021- 2031F |
6.2.4 Sweden Gemcitabine Hydrochloride Market Revenues & Volume, By Pancreatic Cancer, 2021- 2031F |
6.2.5 Sweden Gemcitabine Hydrochloride Market Revenues & Volume, By Others, 2021- 2031F |
7 Sweden Gemcitabine Hydrochloride Market Import-Export Trade Statistics |
7.1 Sweden Gemcitabine Hydrochloride Market Export to Major Countries |
7.2 Sweden Gemcitabine Hydrochloride Market Imports from Major Countries |
8 Sweden Gemcitabine Hydrochloride Market Key Performance Indicators |
8.1 Patient survival rates post gemcitabine hydrochloride treatment |
8.2 Number of clinical trials evaluating gemcitabine hydrochloride in Sweden |
8.3 Adoption rate of gemcitabine hydrochloride in different cancer types |
9 Sweden Gemcitabine Hydrochloride Market - Opportunity Assessment |
9.1 Sweden Gemcitabine Hydrochloride Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.2 Sweden Gemcitabine Hydrochloride Market Opportunity Assessment, By Indication, 2021 & 2031F |
10 Sweden Gemcitabine Hydrochloride Market - Competitive Landscape |
10.1 Sweden Gemcitabine Hydrochloride Market Revenue Share, By Companies, 2024 |
10.2 Sweden Gemcitabine Hydrochloride Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |